CATHOLIC HEALTH INITIATIVES
Memorial Health Care System

PHARMACY AND THERAPEUTICS COMMITTEE

DATE: December 13, 2012 CALLED TO ORDER: 7:00 A.M.
LOCATION: Private Dining Room ADJOURNED: 7:56 A.M.

Members Present:			**Members Absent**:		**Guest**:
Richard Pesce, M.D.	Karen Babb, Pharm.D.	Jackie Jackson, RN, COO	John L. Gwin, Jr., M.D.	Scott Madaris, RN	John Jantz, Pharm.D.
Mark Anderson, M.D.	Diona Brown, RN, C.N.O.	Jane Raulston, RN	Tareck Kadrie, M.D	Deb Moore, RN, SVP	
Samuel Currin, M.D.	Vickie Burger, Lab	Sandy Vredeveld, DPh	Robert Mynatt, M.D.	Nan Payne, RN	
David Dodson, M.D.	Patrick Ellis, Pharm.D.	Beverly Slate, Supply Chain	William Oellerich, M.D.	Melissa Roden, RN	
Nathan Chamberlain, M.D.	Rodney Elliott, CPT		Gwen Davis, RN	Hannah Walker, RN	
Michael Stipanov, M.D	Lila Heet, Pharm.D.		Patrick Hagan, Finance	Elvie Smith, RN	
			Brian Jones, RD, LDN	Don Jones, DPh	

This meeting will be convened under the protection of the Tennessee Statute 63-6-219 and the Health Care Quality Improvement Act of 1986, Public Law 99-660. All information, case reviews, meeting minutes, statistics and correspondence are confidential and protected. Included in that protection are those that are involved in the review of the information. Any discussion of this information outside the realm of Peer Review constitutes a breach and violates the protection of the persons involved in the breach.

AGENDA ITEM	FINDINGS OR CONCLUSION	ACTION, RESPONSIBILITY	STATUS
Minutes	The October 11, 2012 minutes were approved as submitted.		Complete
Therapeutic Interchanges and Formulary Decisions	The following medications were reviewed:		
	1. **Remicade® (Infliximab)** – New policy to be enacted to no longer accept NEW orders unless prior treatment with Humira® or other TNF-antagonist agents has been made and it has been documented that the patient does not tolerate the alternate agents. This change in procedure will not impact any patients currently treated in the infusion center.	1. Approved	Complete
	2. **Exparel® (Bupivacaine Liposomal)** – Liposomal formulation indicated for post-surgical analgesia in bunionectomy and hemorrhoidectomy. Dr. Headrick now requesting this for nerve block s/p thoracic surgery. Due to a lack of data in this area the committee felt they could not formally recommend adding to formulary at this time. Due to the high cost of this medication and probable future requests a financial analysis will be performed and presented to the Value Analysis Steering Committee for final evaluation.	2. To be discussed at Value Analysis Steering Committee	Pending
	3. **Zioptan® (Tafluprost)** – Topical eye drop used for open-angle glaucoma or ocular hypertension. Recommended to not add to formulary and add to existing therapeutic interchange utilizing latanoprost.	3. Not Approved	Complete
	4. **Myrbetriq® (Mirabegron)** – Used in the treatment of overactive bladder. Recommended to add to formulary due to the drug's unique mechanism of action and no similar drugs currently on formulary.	4. Approved	Complete
	5. **Nplate ® (Romiplostim)** – Used in the treatment of refractory thrombocytopenia in patients with ITP. Recommended to add to formulary with use restricted to Hematology service.	5. Approved	Complete
	6. **Stadol NS ® (Butorphanol nasal spray)** – Recommended to remove from formulary.	6. Remove from formulary	Complete
	7. **Pre-Pen (Penicilloyl polylysine) -** Skin test reagent used to identify patients with immune mediated penicillin hypersensitivity in patients with vague or unclear history of penicillin allergy. Recommended to add to formulary with restriction to ID. Protocol/Policy will be developed prior to utilizing this product.	7. Approved	Complete

AGENDA ITEM	FINDINGS OR CONCLUSION	ACTION, RESPONSIBILITY	STATUS
Medication Safety	1. **Xarelto® -** The new indications for this product were reviewed. Pharmacy will be providing education to the Hospitalists and reviewing all orders for rivaroxaban for appropriateness to ensure safe use of this medication. Patient education will also be provided by the pharmacists for all patients newly started on rivaroxaban. 2. **ADR Summary Q1FY13** – ADR summary was reviewed. (1) category 3 ADR was reported this quarter and will be reported to the FDA MedWatch program. An increased trend in antibiotic adverse reactions was observed. 3. **Toradol® (Ketorolac) Dose Limits** – Recommended to institute automatic stop date for total duration of therapy not to exceed 5 total days if no duration of therapy already indicated by the prescriber. This is due to the increased risk of severe adverse effects that can result from prolonged courses of therapy.	1-2. Information 2. Trend will be monitored closely 3. Approved	Complete
Medication Use Evaluation	**Samsca® (Tolvaptan)** - An MUE was conducted to identify the types of prescribers with highest utilization, provide information about expenditures, and determine the usual indications surrounding its use. The findings revealed that the use in CHF patients was often accompanied with the highest beginning serum sodium levels at the time of therapy initiation. These findings will be discussed with the prescribers of highest utilization to determine possible opportunities for improved tolvaptan utilization.	Information	Pending
Policy and Procedure	• **Look – Alike/Sound – Alike Medications Policy –** This policy was reviewed and updated based on updated based on review of previous year's errors and • **Anaphylaxis Reaction Protocol –** Anaphylaxis protocol was developed to assist in the rapid treatment of patients with severe, life-threatening reactions to medications. • **Medication Orders – Pharmacist Review Policy –** This policy was amended to include a statement allowing pharmacists to order necessary laboratory tests in consideration of patient safety and improved patient care when clinically necessary/appropriate. The laboratory tests that may be ordered are pursuant to P&T committee approval or previous committee approvals.	1-3. Approved	Complete
Pharmacy Clinical Dashboard	Committee reviewed.		Complete

There being no further business, the meeting was adjourned at 7:56 A.M. The next P&T meeting is February 14, 2012.

Respectfully submitted,

Sandy Vredeveld, D.Ph. Director of Pharmacy
Patrick Ellis, Pharm.D Pharmacy Clinical Coordinator

Approved by,

Richard Pesce, M.D. Chairman